Hypertrophic Cardiomyopathy: Diagnosis and Therapeutic Options

被引:0
|
作者
Gluckman, Ty J. [1 ]
机构
[1] Providence Heart Inst, Ctr Cardiovasc Analyt Res & Data Sci CARDS, Portland, OR 97225 USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2021年 / 27卷 / 06期
关键词
ALCOHOL SEPTAL ABLATION; SUBAORTIC STENOSIS; CLINICAL PROFILE; NATURAL-HISTORY; DOUBLE-BLIND; TASK-FORCE; DISEASE; MANAGEMENT; VERAPAMIL; OBSTRUCTION;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining asymptomatic and others having significant limitation of functional status. The disorder is typically characterized by left ventricular hypertrophy that is not explained by another cause. Patients are further classified based on whether there is obstruction of the left ventricular outflow tract. To-date, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms.
引用
收藏
页码:S111 / S117
页数:7
相关论文
共 50 条
  • [1] Therapeutic options in hypertrophic cardiomyopathy: A pediatric perspective
    Rhee E.K.
    Nigro J.J.
    Pophal S.G.
    [J]. Current Treatment Options in Cardiovascular Medicine, 2008, 10 (5) : 433 - 441
  • [2] Hypertrophic obstructive cardiomyopathy: Alternative therapeutic options
    Cheng, TO
    [J]. CLINICAL CARDIOLOGY, 1997, 20 (07) : 667 - 667
  • [3] Hypertrophic obstructive cardiomyopathy: Alternative therapeutic options
    Lakkis, N
    Kleiman, N
    Killip, D
    Spencer, WH
    [J]. CLINICAL CARDIOLOGY, 1997, 20 (05) : 417 - 418
  • [4] Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy
    Pasqualucci, Daniele
    Fornaro, Alessandra
    Castelli, Gabriele
    Rossi, Alessandra
    Arretini, Anna
    Chiriatti, Chiara
    Targetti, Mattia
    Girolami, Francesca
    Corda, Marco
    Orru, Pierpaolo
    Matta, Gildo
    Stefano, Pierluigi
    Cecchi, Franco
    Porcu, Maurizio
    Olivotto, Iacopo
    [J]. CIRCULATION-HEART FAILURE, 2015, 8 (06) : 1014 - 1021
  • [5] THE DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY
    KISLYAK, OA
    STOROZHAKOV, GI
    TSYURUPA, TP
    [J]. SOVETSKAYA MEDITSINA, 1984, (02): : 3 - 6
  • [6] The diagnosis of hypertrophic cardiomyopathy
    Wigle, ED
    [J]. HEART, 2001, 86 (06) : 709 - 714
  • [7] New diagnostic options in hypertrophic cardiomyopathy
    Posma, JL
    vanderWall, EE
    Blanksma, PK
    vanderWall, E
    Lie, KI
    [J]. AMERICAN HEART JOURNAL, 1996, 132 (05) : 1031 - 1041
  • [8] Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms
    Ten Berg, JM
    Van Tooren, R
    Jaarsma, W
    Suttorp, MJ
    Plokker, HWM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) : 1485 - 1485
  • [9] Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms
    Fananapazir, L
    McAreavey, D
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 259 - 264
  • [10] Diagnosis and management of hypertrophic cardiomyopathy
    Pantazis A.
    Vischer A.S.
    Perez-Tome M.C.
    Castelletti S.
    [J]. Echo Research & Practice, 2015, 2 (1): : R45 - R53